((自动化翻译由路透提供，请见免责声明 ))
9月25日 - ** 安进 股价下跌多达4.4%，跌至近两个月低点316.22美元
** 如果跌势持续，股价将创下近两个月来最差的一天
** 周二晚些时候，制药商表示，其分别治疗罕见肌肉疾病和皮肤疾病的药物Uplizna和rocatinlimab在后期研究中达到了 (link)。
** 然而，用于治疗特应性皮炎或湿疹的药物rocatinlimab的研究结果却低于已获批的竞争对手的药物。
** 试验结果 "似乎低于 "已获批准的药物，如礼来 的Ebglyss和赛诺菲 -Regeneron的 大片药物Dupixent--经纪公司BMO Capital Markets
** Brokerage Piper Sandler表示，Uplizna很难取代竞争对手Argenx的 Vyvgart，但相信市场规模很大。
** 截至目前，AMGN股价上涨了9.7
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.